Evidence mapPaperPMID 34063950Full record

ReviewJournal of clinical medicine2021

Dysfunctional High-Density Lipoproteins in Type 2 Diabetes Mellitus: Molecular Mechanisms and Therapeutic Implications.

Isabella Bonilha, Francesca Zimetti, Ilaria Zanotti, Bianca Papotti, Andrei C Sposito

Open access · goldAbstract readReview
In one paragraph

Review in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
4.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 40 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Impacts of Plu kaow (Antioxidants (Basel, Switzerland) · 2024
    Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Isabella BonilhaAtherosclerosis and Vascular Biology Laboratory (AtheroLab), Cardiology Department, State University of Campinas (Unicamp), Campinas 13084-971, Brazil.ORCID 0000-0002-5581-5763
Francesca ZimettiDepartment of Food and Drug, University of Parma, 43124 Parma, Italy.ORCID 0000-0002-6665-263X
Ilaria ZanottiDepartment of Food and Drug, University of Parma, 43124 Parma, Italy.ORCID 0000-0003-2701-6021
Bianca PapottiDepartment of Food and Drug, University of Parma, 43124 Parma, Italy.ORCID 0000-0003-3916-7003
Andrei C SpositoAtherosclerosis and Vascular Biology Laboratory (AtheroLab), Cardiology Department, State University of Campinas (Unicamp), Campinas 13084-971, Brazil.ORCID 0000-0001-7127-2052
University of Parma · ITUniversidade Estadual de Campinas (UNICAMP) · BR

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico 301465/2017-7
6 · The paper itself

Abstract

High density lipoproteins (HDLs) are commonly known for their anti-atherogenic properties that include functions such as the promotion of cholesterol efflux and reverse cholesterol transport, as well as antioxidant and anti-inflammatory activities. However, because of some chronic inflammatory diseases, such as type 2 diabetes mellitus (T2DM), significant changes occur in HDLs in terms of both structure and composition. These alterations lead to the loss of HDLs' physiological functions, to transformation into dysfunctional lipoproteins, and to increased risk of cardiovascular disease (CVD). In this review, we describe the main HDL structural/functional alterations observed in T2DM and the molecular mechanisms involved in these T2DM-derived modifications. Finally, the main available therapeutic interventions targeting HDL in diabetes are discussed.

Indexed as

anti-inflammatoryantioxidantcholesterol efflux capacityglycationHDL functionhigh density lipoproteinoxidationtype 2 diabetes mellitusvasodilator

Identifiers

PMID34063950
PMCPMC8196572
OpenAlexW3165413856

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.